Navigation Links
Zamansky & Associates LLC Investigates Affymax Inc. Over Its Recall of Omontys Due to Fatal Reactions

New York, New York (PRWEB) February 26, 2013

Zamansky & Associates LLC notifies all investors in Affymax Inc. (“Affymax”) that it is investigating the recall of Omontys, its anemia treatment for kidney dialysis patients due to reports of fatal reactions. On February 25, 2012, according to Bloomberg News, Affymax’s stock price fell as much as 87 percent after the recall to $2.97 per share, after it had gained 61 percent over the previous 12 months. This investigation concerns potential securities fraud or disclosure violations by Affymax, and its officers and directors, for disclosure failures relating to the fatal reactions which caused the recall.

According to the Notice issued to healthcare providers by Affymax and its marketing partner, the “use of OMONTYS may result in serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal,” and “to date, fatal reactions have been reported in approximately 0.02% of patients following the first dose of intravenous administration.” Reuters reported that the U.S. Food and Drug Administration on Sunday alerted healthcare providers about the recall, and said it had received 19 reports of anaphylaxis from dialysis centers in the United States.

The investigation by Zamansky & Associates LLC concerns whether Affymax knew and failed to disclose the frequency and/or severity of these reactions to Omontys, and the FDA’s response, while its stock price rose over the last year. “If Affymax’s officers and directors knew that its stock price was artificially inflated, and would likely collapse when this news was released to the market, then there was securities fraud or a disclosure law violation,” according to Jake Zamansky.

What Affymax Investors Can Do

If you are a shareholder of Affymax and would like to discuss your legal rights, you may, without obligation or cost to you, email jake (at) zamansky (dot) com or call the law firm at (212) 742-1414.

About Zamansky & Associates

Zamansky & Associates LLC is one of the leading law firms specializing in securities fraud and financial services arbitration and class action litigation. We represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover losses.

To learn more about Zamansky, please visit our website,


Zamansky & Associates, LLC
50 Broadway - 32nd Floor
New York, NY 10004
Jake Zamansky, 212-742-1414

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Michigan’s Exotic Automation & Supply to Exhibit at the 2013 Work Truck Show & Green Truck Summit
2. Parents Recommend Americord over CBR & Viacord
3. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
4. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
5. DuPont Tate & Lyle Bio Products Announces Winner of Zemea® Innovation Award
6. Industry Thought Leader to Present Transformational Opportunities for Industry Adoption of Advanced Analytics at 2013 HIMSS Annual Conference & Exhibition
7. Global Biopesticides Market Trends & Forecasts (2012 – 2017)
8. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
9. Corporate Financial Planning Experts Gather at IE – Innovation Enterprise’s Financial Planning & Analysis for Pharma & Biotech Summit
10. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
11. The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... 2015 , ... The Academy of Model Aeronautics (AMA), led by its Executive ... Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. , FPV racing ... this type of racing and several new model aviation pilots have joined the community ...
(Date:11/24/2015)... AVIV, Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: ... held on December 29, 2015 at 11:00 a.m. Israel ... Co., Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... election of Eric Paneth and Izhak Tamir to ... and Rami Skaliter as external directors; , approval of an amendment ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig ... report titled, "DNA Synthesis and Biosecurity: Lessons Learned and ... Department of Health and Human Services guidance for synthetic ... 2010. --> --> ... also has the potential to pose unique biosecurity threats. ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/29/2015)... , October 29, 2015 ... authentication company focused on the growing mobile commerce ... announces that StackCommerce, a leading marketplace to discover ... the Wocket® smart wallet on StackSocial for this ... ("NXT-ID" or the "Company"), a biometric authentication company ...
Breaking Biology News(10 mins):